Trials / Completed
CompletedNCT04878913
Retrospective Evaluation of Lung Pathology in Subjects With COVID-19
Non-interventional, Retrospective, Multicenter, Follow-up Study Evaluating the Effect of C21 on Lung Pathology in Subjects Previously Hospitalized With COVID-19 and Enrolled in the VP-C21-006 Trial
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 35 (actual)
- Sponsor
- Vicore Pharma AB · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Non-interventional, retrospective, multi-center, follow-up study evaluating the effect of C21 on lung pathology in subjects previously hospitalised with COVID-19 and enrolled in the VP-C21-006 trial.
Detailed description
The study will collect available HRCT scans obtained prior to, during treatment with C21 or placebo and up to 24 weeks after trial completion. HRCT scans will be assessed for ground glass opacity, reticulation, band opacity, fibrosis and consolidation by a central, blinded HRCT reader.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | C21 | C21 was administered in the VP-C21-006 trial |
| DRUG | Placebo | Placebo was administered in the VP-C21-006 trial |
Timeline
- Start date
- 2021-07-07
- Primary completion
- 2021-08-23
- Completion
- 2021-08-23
- First posted
- 2021-05-10
- Last updated
- 2024-09-04
Locations
4 sites across 1 country: India
Source: ClinicalTrials.gov record NCT04878913. Inclusion in this directory is not an endorsement.